2023 World Conference on Lung Cancer (Posters)-P1.21. Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC)

P1.21. Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC) - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the predictive value of the eosinophil-to-neutrophil ratio (ENR) and neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic non-small cell lung cancer (mNSCLC) receiving immunotherapy. The researchers found that a higher peak ENR was associated with a favorable response and longer duration of response, progression-free survival, and overall survival. In contrast, the baseline NLR was lower in patients with a favorable response, but it did not have a significant effect on survival outcomes. These findings suggest that the ENR, but not the NLR, can predict the efficacy of immunotherapy in mNSCLC patients. Further research is necessary to understand how eosinophils, neutrophils, and lymphocytes interact within the tumor microenvironment to optimize immunotherapy efficacy.

Asset Subtitle

Joe Wei

Meta Tag

Speaker Joe Wei

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

predictive value

eosinophil-to-neutrophil ratio

ENR

neutrophil-to-lymphocyte ratio

NLR

metastatic non-small cell lung cancer

immunotherapy

response

progression-free survival

tumor microenvironment